Discover Cures for Genetic Diseases with Rosebud Biosciences
Discover Cures for Genetic Diseases with Rosebud Biosciences
Discover Cures for Genetic Diseases with Rosebud Biosciences
Between 5 and 10 percent of humanity has a rare disease, half of whom are children. The future can be especially tragic for these youngest patients - 30% won’t live to see their 5th birthday.
This is because only 5% of rare diseases have approved treatments. We want Rosebud to find cures for that remaining 95%.
Between 5 and 10 percent of humanity has a rare disease, half of whom are children. The future can be especially tragic for these youngest patients - 30% won’t live to see their 5th birthday.
This is because only 5% of rare diseases have approved treatments. We want Rosebud to find cures for that remaining 95%.
Between 5 and 10 percent of humanity has a rare disease, half of whom are children. The future can be especially tragic for these youngest patients - 30% won’t live to see their 5th birthday.
This is because only 5% of rare diseases have approved treatments. We want Rosebud to find cures for that remaining 95%.
Learn More
WHO WE ARE
Genetic diseases are a huge unmet need
Genetic diseases are a huge unmet need
Rosebud Biosciences is an early stage startup that develops therapies for rare genetic diseases in children. We do this by modeling human development with organoids that have the same gene mutation as the child, and screen drugs in these models to find cures.
Rosebud Biosciences is an early stage startup that develops therapies for rare genetic diseases in children. We do this by modeling human development with organoids that have the same gene mutation as the child, and screen drugs in these models to find cures.
95%
Genetic diseases have no targeted treatments
95%
Of genetic diseases have no targeted treatments
95%
Of genetic diseases have no targeted treatments
350 million
People worldwide suffer from a genetic disease
350 million
People worldwide suffer from a genetic disease
350 million
People worldwide suffer from a genetic disease
30%
Half are children and 30% won’t see their 5th birthday
30%
Half are children and 30% won’t see their 5th birthday
30%
Half are children and 30% won’t see their 5th birthday
95%
Of genetic diseases have no targeted treatments
TECHNOLOGY
Revolutionizing treatments for children's rare genetic diseases
We develop targeted therapies by modeling human development with organoids that replicate the child's genetic mutations, accelerating the search for effective cures.
Organoid Platform
Cardiac Organoids
Hepatic Organoids
Neural Organoids
In Progress
Kidney Organoids
In Progress
Organoid Platform
We model genetic diseases using micropatterned organoids from disease-specific Human Induced Pluripotent Stem Cells (hiPSCs), which have major advantages over conventional hiPSC disease modeling. Our circular “2.5D” organoids contain cells from multiple lineages (e.g., embryonic germ layers, endothelial, smooth muscle, fibroblasts) and are differentiated from hiPSCs without the need for complex biopolymer matrices, specialized tissue culture plates, or mixing of differentiated cell types.
Due to the relative ease in editing pathogenic mutations in or out of hiPSCs compared to animal models and primary cells, as well as the scale at which they can be produced in a 100% human biological system, hiPSC-derived organoids are ideal for screening small molecules, RNA therapies (e.g., ASOs, siRNAs), CRISPR and other gene therapies, immunotherapies, and more.
Rosebud models human development in a dish
Rosebud emphasizes longitudinal monitoring of organoids as they transition from the embryonic to the differentiated tissue state. The developing organoids are longitudinally imaged via live cell brightfield microscopy, which can be complemented with biomarker monitoring (e.g., immunostaining, secreted protein ELISAs) and calcium assays.
Longitudinal surveillance of organoid development
We scale up drug discovery using organoid models, robotics, and machine learning
Up to 10,000 organoids, each with the patient’s genetic mutation, are simultaneously and continuously monitored for disease progression.
TECHNOLOGY
Revolutionizing treatments for children's rare genetic diseases
We develop targeted therapies by modeling human development with organoids that replicate the child's genetic mutations, accelerating the search for effective cures.
Organoid Platform
Cardiac Organoids
Hepatic Organoids
Neural Organoids
In Progress
Kidney Organoids
In Progress
Organoid Platform
We model genetic diseases using micropatterned organoids from disease-specific Human Induced Pluripotent Stem Cells (hiPSCs), which have major advantages over conventional hiPSC disease modeling. Our circular “2.5D” organoids contain cells from multiple lineages (e.g., embryonic germ layers, endothelial, smooth muscle, fibroblasts) and are differentiated from hiPSCs without the need for complex biopolymer matrices, specialized tissue culture plates, or mixing of differentiated cell types.
Due to the relative ease in editing pathogenic mutations in or out of hiPSCs compared to animal models and primary cells, as well as the scale at which they can be produced in a 100% human biological system, hiPSC-derived organoids are ideal for screening small molecules, RNA therapies (e.g., ASOs, siRNAs), CRISPR and other gene therapies, immunotherapies, and more.
Rosebud models human development in a dish
Rosebud emphasizes longitudinal monitoring of organoids as they transition from the embryonic to the differentiated tissue state. The developing organoids are longitudinally imaged via live cell brightfield microscopy, which can be complemented with biomarker monitoring (e.g., immunostaining, secreted protein ELISAs) and calcium assays.
Longitudinal surveillance of organoid development
We scale up drug discovery using organoid models, robotics, and machine learning
Up to 10,000 organoids, each with the patient’s genetic mutation, are simultaneously and continuously monitored for disease progression.
TECHNOLOGY
Revolutionizing treatments for children's rare genetic diseases
We develop targeted therapies by modeling human development with organoids that replicate the child's genetic mutations, accelerating the search for effective cures.
Organoid Platform
Cardiac Organoids
Hepatic Organoids
Neural Organoids
In Progress
Kidney Organoids
In Progress
Organoid Platform
We model genetic diseases using micropatterned organoids from disease-specific Human Induced Pluripotent Stem Cells (hiPSCs), which have major advantages over conventional hiPSC disease modeling. Our circular “2.5D” organoids contain cells from multiple lineages (e.g., embryonic germ layers, endothelial, smooth muscle, fibroblasts) and are differentiated from hiPSCs without the need for complex biopolymer matrices, specialized tissue culture plates, or mixing of differentiated cell types.
Due to the relative ease in editing pathogenic mutations in or out of hiPSCs compared to animal models and primary cells, as well as the scale at which they can be produced in a 100% human biological system, hiPSC-derived organoids are ideal for screening small molecules, RNA therapies (e.g., ASOs, siRNAs), CRISPR and other gene therapies, immunotherapies, and more.
Rosebud models human development in a dish
Rosebud emphasizes longitudinal monitoring of organoids as they transition from the embryonic to the differentiated tissue state. The developing organoids are longitudinally imaged via live cell brightfield microscopy, which can be complemented with biomarker monitoring (e.g., immunostaining, secreted protein ELISAs) and calcium assays.
Longitudinal surveillance of organoid development
We scale up drug discovery using organoid models, robotics, and machine learning
Up to 10,000 organoids, each with the patient’s genetic mutation, are simultaneously and continuously monitored for disease progression.
PARTNERSHIP
Let us empower your drug development
Let us empower your drug development
Let us empower your drug development
Rosebud is actively looking for pharma partners so we can empower other drug development teams with our mutation-specific organoid platform. We’re just getting started and are seeking partners interested in heart, liver, neural or kidney disease drug therapies.
Rosebud is actively looking for pharma partners so we can empower other drug development teams with our mutation-specific organoid platform. We’re just getting started and are seeking partners interested in heart, liver, neural or kidney disease drug therapies.
Rosebud is actively looking for pharma partners so we can empower other drug development teams with our mutation-specific organoid platform. We’re just getting started and are seeking partners interested in heart, liver, neural or kidney disease drug therapies.
Contact Us
OUR TEAM
Meet the Minds Behind Rosebud
Meet the Minds Behind Rosebud
CEO
Kitch Wilson, MD, PhD
Kitch is a Stanford- and Duke-trained Physician-Scientist with over 16 years of experience merging human induced pluripotent stem cells (hiPSCs) with genomic and molecular technologies.
CTO
Evan Lyall, PhD
Evan is a UC Berkeley-trained Scientist-Engineer with over 10 years of experience in advanced microscopy, data engineering, and machine learning.
SENIOR SCIENTIST
Aditya Khedkar, MS
Aditya is a Boston University- and Johns Hopkins-trained scientist with over 9 years of experience in gene editing and stem cell biology.
OPPORTUNITY
CONTACT US
Speak with a team member
Speak with a team member
Speak with a team member
Rosebud is a science-first organization that offers best-in-class products and technical support. Our team of experts is standing by to help you succeed.
Rosebud is a science-first organization that offers best-in-class products and technical support. Our team of experts is standing by to help you succeed.
Rosebud is a science-first organization that offers best-in-class products and technical support. Our team of experts is standing by to help you succeed.
